TTF1 and non-small cell lung carcinoma: However, this TTF-1-dependent, heightened cisplatin sensitivity did not extend to another platinum chemotherapy – carboplatin (Fig. S2A,B); nor could we detect a TTF-1-dependent differential sensitivity toward gemcitabine (Fig. S2C,D), a chemotherapy sometimes used in combination with cisplatin for advanced nonsmall cell lung cancer (NSCLC)26.